Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Breast 1

Conditions

Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Rectal Neoplasms 1Endometrial Neoplasms 1Advanced Solid Tumors 1

Interventions

Bevacizumab 112Fluorouracil 98Oxaliplatin 96Leucovorin 96Irinotecan 86Capecitabine 73Cetuximab 64Panitumumab 42pembrolizumab 38regorafenib 28Nivolumab 23IFL protocol 22Folfox protocol 21trifluridine tipiracil drug combination 14Radiotherapy 13durvalumab 11Gemcitabine 10Celecoxib 9tremelimumab 7binimetinib 7aflibercept 7Drug Therapy 7Disulfides 7Cyclophosphamide 7Trifluridine 6Trastuzumab 6Sunitinib 6Immunoglobulin G 6Colonoscopy 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Colorectal Neoplasms × HMPL-013 × Clear all
NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
52 enrolled 23 charts
BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04322539 2025-04-04

FRESCO-2

Hutchmed

Phase 3 Completed
691 enrolled 26 charts 1 FDA
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02196688 2020-06-16

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Hutchmed

Phase 2 Completed
71 enrolled 13 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡